Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees.  The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Incyte Corp. adalah perusahaan biopharmaceutical yang bergerak dalam penemuan, pengembangan, dan komersialisasi terapi proprietari. Perusahaan ini berkantor pusat di Wilmington, Delaware dan saat ini mempekerjakan 2.844 karyawan penuh waktu. Perusahaan ini beroperasi di dua area terapeutik. Salah satu area terapeutik adalah Hematologi/Onkologi, yang mencakup Neoplasma Mieloproliferatif dan Penyakit Graft-Versus-Host, serta tumor padat dan keganasan hematologis. Area terapeutik lainnya adalah Inflamasi dan Autoimunitas, yang mencakup waralaba komersial Dermatologinya. Waralaba hematologi dan onkologi perusahaan terdiri dari enam produk, yaitu JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), dan ZYNYZ (retifanlimab-dlwr), serta berbagai program pengembangan klinis. Saluran pengembangan perusahaan juga mencakup dua antagonis molekul kecil pertama di kelasnya terhadap reseptor terkait-Mas (MRGPRX2) dan INCB000547, sebuah antagonis MRGPRX4 oral.

Incyte

Google

Apple

Microsoft

Amazon

Broadcom

Meta Platforms

Eli Lilly

JPMorgan

Oracle

Exxon Mobil

Johnson & Johnson

ASML

MasterCard

SPDR S&P500 ETF

Palantir

Costco

Bank of America

General Electric

Procter & Gamble

Vanguard Total Stock Market ETF

Toyota

Caterpillar

AstraZeneca

Cisco

Goldman Sachs

Lam Research

Wells Fargo

Merck

Novo Nordisk

Novartis

Raytheon Technologies

Philip Morris

Applied Materials

American Express

Royal Bank of Canada

Intel

Abbott

Salesforce

Shell

T-Mobile

Intuitive Surgical

Disney

Shopify

Invesco QQQ Trust

Blackstone

PepsiCo

Boeing

Charles Schwab

Amgen

QUALCOMM

Texas Instruments

S&P Global

Verizon

Arista Networks

Lowe's

Capital One

Southern Copper

Honeywell

Sony

Pfizer

Unilever

Deere

TotalEnergies

ServiceNow

Adobe

Palo Alto Networks

ConocoPhillips

Medtronic

Progressive

Chubb

CrowdStrike

Sanofi

Vertex Pharmaceuticals

Bristol-Myers Squibb

Comcast

Vanguard Dev Markets ETF

Mercadolibre

Starbucks

Enbridge

Carvana

Agnico Eagle

General Dynamics

Vanguard Value ETF

Robinhood

Moody's

Nike

Northrop Grumman

Vanguard Total Bond Market ETF

Duke Energy

Scotiabank

Barclays

Doordash Inc

Marsh & McLennan

NetEase

Saham Incyte

Tentang Incyte

Statistik Kunci

Pengguna Lain Sedang Membeli